Baseline characteristics
| Characteristic . | ALL . | CPI . | No prior CPI . | P value . |
|---|---|---|---|---|
| No. of patients | N = 2186 | n = 600 | n = 1586 | |
| Data source, n (%) | ||||
| CIBMTR | 403 (18.4) | 138 (23) | 265 (16.7) | 7.00E-04 |
| EBMT | 1783 (81.6) | 462 (77) | 1321 (83.3) | |
| Year of HCT, median (range) | 2017 (2008-2023) | 2019 (2015-2023) | 2015 (2008-2023) | <.0001 |
| FU of alive patients, median (IQR), mo | 27.77 (12-60) | 16.5 (5.1-33.6) | 39 (12.8-73.1) | <.0001 |
| Age, median (IQR), y | 32.27 (25.9-41.3) | 31.7 (26-41.4) | 32.4 (25.7-41.3) | .6632 |
| Sex, n (%) | ||||
| Female | 849 (38.9) | 205 (34.2) | 644 (40.6) | .0061 |
| Male | 1335 (61.1) | 394 (65.8) | 941 (59.4) | |
| Missing | 2 | 1 | 1 | |
| Donor type, n (%) | ||||
| Haploidentical donor | 803 (36.7) | 281 (46.8) | 522 (32.9) | <.0001 |
| HLA-identical sibling | 730 (33.4) | 159 (26.5) | 571 (36) | |
| HLA-MUD | 653 (29.9) | 160 (26.7) | 493 (31.1) | |
| Prior auto-HCT, n (%) | ||||
| No prior auto-HCT | 634 (29) | 226 (37.7) | 408 (25.8) | <.0001 |
| Prior auto-HCT | 1549 (71) | 374 (62.3) | 1175 (74.2) | |
| Missing | 3 | 0 | 3 | |
| Disease status at HCT, n (%) | ||||
| Refractory | 427 (19.5) | 90 (15) | 337 (21.2) | .003 |
| CR | 1074 (49.1) | 307 (51.2) | 767 (48.4) | |
| PR | 605 (27.7) | 187 (31.2) | 418 (26.4) | |
| Unknown | 75 (3.4) | 15 (2.5) | 60 (3.8) | |
| Untreated | 5 (0.2) | 1 (0.2) | 4 (0.3) | |
| Time from last dose of CPI | ||||
| Median (range) [IQR], mo | 10.1 (0.7-217.2) [5.6-22.9] | |||
| Missing | 53 | |||
| Conditioning, n (%) | ||||
| MAC | 413 (18.9) | 105 (17.5) | 308 (19.4) | .3062 |
| RIC/NMA | 1773 (81.1) | 495 (82.5) | 1278 (80.6) | |
| GVHD prevention, n (%) | ||||
| CNI + MMF ± other(s) (except post-Cy) | 528 (24.2) | 119 (19.8) | 409 (25.8) | <.0001 |
| CNI + MTX ± other(s) (except MMF, post-Cy) | 768 (35.1) | 146 (24.3) | 622 (39.2) | |
| Post-Cy ± other(s) | 890 (40.7) | 335 (55.8) | 555 (35) | |
| Missing | 0 | 0 | 0 | |
| ATG,∗ n (%) | ||||
| ATG | 456 (25.6) | 132 (28.6) | 324 (24.5) | .0863 |
| No ATG | 1327 (74.4) | 330 (71.4) | 997 (75.5) | |
| Race, n (%) | ||||
| Black or African American | 34 (1.6) | 14 (2.3) | 20 (1.3) | .0105 |
| Missing | 1828 (83.6) | 477 (79.5) | 1351 (85.2) | |
| Other | 19 (0.9) | 7 (1.2) | 12 (0.8) | |
| White | 305 (14) | 102 (17) | 203 (12.8) | |
| KPS, n (%) | ||||
| <90 | 482 (22.8) | 126 (21.7) | 356 (23.2) | .2946 |
| ≥90 | 1621 (76.7) | 449 (77.4) | 1172 (76.4) | |
| Not reported | 11 (0.5) | 5 (0.9) | 6 (0.4) | |
| Missing | 72 | 20 | 52 | |
| HCT-CI, n (%) | ||||
| 0 | 984 (45) | 300 (50) | 684 (43.1) | <.0001 |
| 1-2 | 322 (14.7) | 118 (19.7) | 204 (12.9) | |
| ≥3 | 362 (16.6) | 143 (23.8) | 219 (13.8) | |
| Missing | 518 (23.7) | 39 (6.5) | 479 (30.2) |
| Characteristic . | ALL . | CPI . | No prior CPI . | P value . |
|---|---|---|---|---|
| No. of patients | N = 2186 | n = 600 | n = 1586 | |
| Data source, n (%) | ||||
| CIBMTR | 403 (18.4) | 138 (23) | 265 (16.7) | 7.00E-04 |
| EBMT | 1783 (81.6) | 462 (77) | 1321 (83.3) | |
| Year of HCT, median (range) | 2017 (2008-2023) | 2019 (2015-2023) | 2015 (2008-2023) | <.0001 |
| FU of alive patients, median (IQR), mo | 27.77 (12-60) | 16.5 (5.1-33.6) | 39 (12.8-73.1) | <.0001 |
| Age, median (IQR), y | 32.27 (25.9-41.3) | 31.7 (26-41.4) | 32.4 (25.7-41.3) | .6632 |
| Sex, n (%) | ||||
| Female | 849 (38.9) | 205 (34.2) | 644 (40.6) | .0061 |
| Male | 1335 (61.1) | 394 (65.8) | 941 (59.4) | |
| Missing | 2 | 1 | 1 | |
| Donor type, n (%) | ||||
| Haploidentical donor | 803 (36.7) | 281 (46.8) | 522 (32.9) | <.0001 |
| HLA-identical sibling | 730 (33.4) | 159 (26.5) | 571 (36) | |
| HLA-MUD | 653 (29.9) | 160 (26.7) | 493 (31.1) | |
| Prior auto-HCT, n (%) | ||||
| No prior auto-HCT | 634 (29) | 226 (37.7) | 408 (25.8) | <.0001 |
| Prior auto-HCT | 1549 (71) | 374 (62.3) | 1175 (74.2) | |
| Missing | 3 | 0 | 3 | |
| Disease status at HCT, n (%) | ||||
| Refractory | 427 (19.5) | 90 (15) | 337 (21.2) | .003 |
| CR | 1074 (49.1) | 307 (51.2) | 767 (48.4) | |
| PR | 605 (27.7) | 187 (31.2) | 418 (26.4) | |
| Unknown | 75 (3.4) | 15 (2.5) | 60 (3.8) | |
| Untreated | 5 (0.2) | 1 (0.2) | 4 (0.3) | |
| Time from last dose of CPI | ||||
| Median (range) [IQR], mo | 10.1 (0.7-217.2) [5.6-22.9] | |||
| Missing | 53 | |||
| Conditioning, n (%) | ||||
| MAC | 413 (18.9) | 105 (17.5) | 308 (19.4) | .3062 |
| RIC/NMA | 1773 (81.1) | 495 (82.5) | 1278 (80.6) | |
| GVHD prevention, n (%) | ||||
| CNI + MMF ± other(s) (except post-Cy) | 528 (24.2) | 119 (19.8) | 409 (25.8) | <.0001 |
| CNI + MTX ± other(s) (except MMF, post-Cy) | 768 (35.1) | 146 (24.3) | 622 (39.2) | |
| Post-Cy ± other(s) | 890 (40.7) | 335 (55.8) | 555 (35) | |
| Missing | 0 | 0 | 0 | |
| ATG,∗ n (%) | ||||
| ATG | 456 (25.6) | 132 (28.6) | 324 (24.5) | .0863 |
| No ATG | 1327 (74.4) | 330 (71.4) | 997 (75.5) | |
| Race, n (%) | ||||
| Black or African American | 34 (1.6) | 14 (2.3) | 20 (1.3) | .0105 |
| Missing | 1828 (83.6) | 477 (79.5) | 1351 (85.2) | |
| Other | 19 (0.9) | 7 (1.2) | 12 (0.8) | |
| White | 305 (14) | 102 (17) | 203 (12.8) | |
| KPS, n (%) | ||||
| <90 | 482 (22.8) | 126 (21.7) | 356 (23.2) | .2946 |
| ≥90 | 1621 (76.7) | 449 (77.4) | 1172 (76.4) | |
| Not reported | 11 (0.5) | 5 (0.9) | 6 (0.4) | |
| Missing | 72 | 20 | 52 | |
| HCT-CI, n (%) | ||||
| 0 | 984 (45) | 300 (50) | 684 (43.1) | <.0001 |
| 1-2 | 322 (14.7) | 118 (19.7) | 204 (12.9) | |
| ≥3 | 362 (16.6) | 143 (23.8) | 219 (13.8) | |
| Missing | 518 (23.7) | 39 (6.5) | 479 (30.2) |
CNI, calcineurin inhibitor; FU, follow-up; MMF, mycophenolate mofetil; NMA, nonmyeloablative.
ATG data missing for CIBMTR.